L
LimmaTech Biologics
Innovative vaccines combating antimicrobial resistance with proprietary multivalent technology
About LimmaTech Biologics
LimmaTech Biologics AG, based in Schlieren Zurich, Switzerland, is a clinical stage biopharmaceutical company specializing in the development of innovative vaccines to combat antimicrobial resistant pathogens. The company leverages its proprietary self-adjuvanting and multi-antigen vaccine platform, alongside additional disease-specific vaccine approaches, to prevent increasingly untreatable microbial infections. LimmaTech's pioneering vaccine development technologies have built a robust pipeline of vaccine programs aimed at protecting against and preventing severe infections caused by pathogens resistant to antimicrobial treatments. The company serves healthcare providers and institutions globally, operating within the biopharmaceutical market. LimmaTech generates revenue through the development and commercialization of its vaccine candidates, as well as potential partnerships and licensing agreements. The business model focuses on leveraging decades of experience in vaccine technologies and pathogen understanding to tailor vaccine approaches that protect lives and reduce the threat of microbial resistance.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2015
- Headquarters
- Schlieren, Switzerland
- Employees
- 57
- Open positions
- 2
- Dealroom signal
- 74.9/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Vaccines, Biotech and Pharma, Woman Founder, DT and LS, science-based, Swiss DT Biotech
- Business model
- Manufacturing
- Client focus
- b2b
- Investment activity
- 1 company, latest Nov 2021
- Capital deployed
- $49M
- Preferred round
- SERIES A
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | May 2026 | $0 | $780M | Eli Lilly | ↗ |
| GRANT✓Other financing | Feb 2024 | $2.2M | — | CARB-X | ↗ |
Growth signals
Latest recorded traffic for LimmaTech Biologics is 5.3K monthly website visits, up 783.3% over the last three months. LimmaTech Biologics's team grew 3.6% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
CARB-X
Series A4 investors entered at this stage
AXA Investment Managers
Repair Impact Fund
Adjuvant Capital
Tenmile
Other known investors1 additional known investor
Eli Lilly
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about LimmaTech Biologics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See LimmaTech Biologics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.